Treatment strategy for Henoch-Schönlein purpura nephritis

Henoch-Schönlein purpura nephritis.

Henoch-Schönlein purpura (HSP) is a systemic vasculitic disorder first reported by Heberden in 1806. The association of purpura and joint pain was described by Schönlein in 1837, who termed it “peliosis rheumatica.” Henoch added a description of four children with skin lesions associated with colicky abdominal pain, gastrointestinal hemorrhage, and joint pain in 1874, and in 1899 pointed out th...

Chapter 11: Henoch-Schönlein purpura nephritis

11.1: Treatment of HSP nephritis in children 11.1.1: We suggest that children with HSP nephritis and persistent proteinuria, 40.5-1 g/d per 1.73 m, are treated with ACE-I or ARBs. (2D) 11.1.2: We suggest that children with persistent proteinuria, 41 g/d per 1.73 m, after a trial of ACE-I or ARBs, and GFR 450 ml/min per 1.73 m, be treated the same as for IgAN with a 6-month course of corticoster...

Azathioprine treatment in two children with Henoch–Schönlein purpura nephritis

Henoch-Schönlein purpura.

Henoch-Schönlein purpura commonly occurs in children at about age five. There is no known etiologic agent. The illness is characterized by skin rash, joint pain, edema and gastrointestinal symptoms. Laboratory tests are not diagnostic. Although there is no specific treatment, steroids may help prevent serious gastrointestinal complications. Prognosis is good, except for those patients with adva...

Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management.

BACKGROUND Henoch-Schönlein purpura (HSP) is one of the most common vasculitides in children. It is manifested by skin purpura, arthritis, abdominal pain, renal involvement, etc. Typically, HSP is considered to be self-limiting, although renal involvement (HSP purpura nephritis, HSPN) is the principal cause of morbidity from this disease. For this reason, it is important to clarify the mechanis...